CYSTIC FIBROSIS

Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial

A Clement¹, A Tamalet¹, E Leroux², S Ravilly², B Fauroux¹, J-P Jais³

¹ AP-HP, Hôpital Trousseau, Pediatric Pulmonary Department, Paris; Inserm, U719, Paris; and Université Pierre et Marie Curie-Paris 6, Paris, France
² Cystic Fibrosis Association Vaincre la Mucoviscidose, Paris, France
³ AP-HP, Hôpital Necker, Biostatistic Department, Paris; and Université René Descartes-Paris 5, Paris, France

Correspondence to:
Dr B Fauroux
AP-HP, Hôpital Trousseau, Pediatric Pulmonary Department, Inserm, U719, Université Pierre et Marie Curie-Paris 6, 26 Avenue du Docteur Arnold Netter, 75571 Paris cedex 12, France; brigitte.fauroux{at}trs.aphp.fr

Background: Macrolides display immunomodulatory effects that may be beneficial in chronic inflammatory pulmonary diseases. The aim of the study was to document whether long term use of azithromycin may be associated with respiratory benefits in young patients with cystic fibrosis.

Methods: A multicentre, randomised, double blind, placebo controlled trial was conducted from October 2001 to June 2003. The criteria for enrolment were age older than 6 years and forced expiratory volume in 1 second (FEV₁) of 40% or more. The active group received either 250 mg or 500 mg (body weight < or 40 kg) of oral azithromycin three times a week for 12 months. The primary end point was change in FEV₁.

Results: Eighty two patients of mean (SD) age 11.0 (3.3) years and mean (SD) FEV₁ 85 (22)% predicted were randomised: 40 in the azithromycin group and 42 in the placebo group. Nineteen patients were infected with Pseudomonas aeruginosa. The relative change in FEV₁ at month 12 did not differ significantly between the two groups. The number of pulmonary exacerbations (count ratio 0.50 (95% CI 0.32 to 0.79), p<0.005), the time elapsed before the first pulmonary exacerbation (hazard ratio 0.37 (95% CI 0.22 to 0.63), p<0.0001), and the number of additional courses of oral antibiotics were significantly reduced in the azithromycin group regardless of the infectious status (count ratio 0.55 (95% CI 0.36 to 0.85), p<0.01). No severe adverse events were reported.

Conclusion: Long term use of low dose azithromycin in young patients with cystic fibrosis has a beneficial effect on lung disease expression, even before infection with Pseudomonas aeruginosa.

Abbreviations: CF, cystic fibrosis; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity

Keywords: children; cystic fibrosis; azithromycin; lung function; respiratory exacerbation

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2006 61: 831. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Meyer, M., Huaux, F., Gavilanes, X., van den Brule, S., Lebecque, P., Lo Re, S., Lison, D., Scholte, B., Wallemacq, P., Leal, T. (2009). Azithromycin Reduces Exaggerated Cytokine Production by M1 Alveolar Macrophages in Cystic Fibrosis. Am. J. Respir. Cell Mol. Bio. 41: 590-602 [Abstract] [Full Text]  
• Retsch-Bogart, G. Z., Quittner, A. L., Gibson, R. L., Oermann, C. M., McCoy, K. S., Montgomery, A. B., Cooper, P. J. (2009). Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis. Chest 135: 1223-1232 [Abstract] [Full Text]  
• Idris, S. F, Chilvers, E. R, Haworth, C., McKeon, D., Condliffe, A. M (2009). Azithromycin therapy for neutrophilic airways disease: myth or magic?. Thorax 64: 186-189 [Full Text]  
• Abbott, J (2009). Health-related quality of life measurement in cystic fibrosis: advances and limitations. Chronic Respiratory Disease 6: 31-41 [Abstract]  
• Crosbie, P. A. J., Woodhead, M. A. (2009). Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 33: 171-181 [Abstract] [Full Text]  
• Kunisaki, K. M., Niewoehner, D. E. (2008). Antibiotic Prophylaxis for Chronic Obstructive Pulmonary Disease: Resurrecting an Old Idea. Am. J. Respir. Crit. Care Med. 178: 1098-1099 [Full Text]  
• Seemungal, T. A. R., Wilkinson, T. M. A., Hurst, J. R., Perera, W. R., Sapsford, R. J., Wedzicha, J. A. (2008). Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations. Am. J. Respir. Crit. Care Med. 178: 1139-1147 [Abstract] [Full Text]  
• McCoy, K. S., Quittner, A. L., Oermann, C. M., Gibson, R. L., Retsch-Bogart, G. Z., Montgomery, A. B. (2008). Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 178: 921-928 [Abstract] [Full Text]  
• Kirk, C. B (2008). IS THE FREQUENCY OF RECURRENT CHEST INFECTIONS, IN CHILDREN WITH CHRONIC NEUROLOGICAL PROBLEMS, REDUCED BY PROPHYLACTIC AZITHROMYCIN?. Arch. Dis. Child. 93: 442-444 [Full Text]  
• Ware, L. B. (2007). Clinical Year in Review III: Asthma, Lung Transplantation, Cystic Fibrosis, Acute Respiratory Distress Syndrome. Proc Am Thorac Soc 4: 489-493 [Full Text]  
• McCormack, J., Bell, S., Senini, S., Walmsley, K., Patel, K., Wainwright, C., Serisier, D., Harris, M., Bowler, S. (2007). Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 30: 487-495 [Abstract] [Full Text]  
• Mayer-Hamblett, N., Ramsey, B. W., Kronmal, R. A. (2007). Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis. Proc Am Thorac Soc 4: 370-377 [Abstract] [Full Text]  
• Goss, C. H., Quittner, A. L. (2007). Patient-reported Outcomes in Cystic Fibrosis. Proc Am Thorac Soc 4: 378-386 [Abstract] [Full Text]  
• Bell, S. C, Robinson, P. J (2007). Exacerbations in cystic fibrosis: 2 {middle dot} Prevention. Thorax 62: 723-732 [Abstract] [Full Text]  
• Accurso, F. J. (2007). Update in Cystic Fibrosis 2006. Am. J. Respir. Crit. Care Med. 175: 754-757 [Full Text]  
• Enderby, B., Doull, I. (2007). Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?. Arch. Dis. Child. 92: 195-196 [Full Text]